Cost-effectiveness analysis and prevention effects of ultra-orphan drugs for rare diseases: an in silico model applied to Cryopyrin Associated Periodic Syndromes (CAPS)

Podobne knjige/članki

• The RaDiCEA Project: cost of illness (COI) analysis applied to Cryopyrin Associated Periodic Syndromes (CAPS)
  od: Della Casa Alberighi, O, et al.
  Izdano: (2015)
• PW02-027 - CAPS and cost-effectiveness analysis project
  od: Alberighi, O Della Casa, et al.
  Izdano: (2013)
• National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
  od: Bibalo, C, et al.
  Izdano: (2011)
• Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
  od: Martini A, et al.
  Izdano: (2011-09-01)
• Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
  od: Caorsi, R, et al.
  Izdano: (2011)